Condition

B-ALL clinical trials and research

• 14Clinical trials
• 12NIH research projects
• 2Countries

Newest B-ALL clinical trials

All recruiting trials (14)

• TSLPR-CART therapy for CRLF2-R/TSLPR–expressing B-ALL in adults

  This study tests a CAR T-cell treatment called TSLPR-CART in adults whose B-ALL cells overexpress TSLPR and have not responded to standard therapy.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07572136

• CD19 CAR-T versus donor lymphocyte infusion for clearing MRD after allogeneic stem cell transplant in Ph-negative B-ALL

  This trial tests whether a single infusion of autologous CD19 CAR-T cells or chemotherapy plus donor lymphocyte infusion better clears minimal residual disease in patients aged 3–79 with Ph-negative B‑cell ALL after allogeneic stem cell transplant.

  Recruiting Phase 3 Peking University People's Hospital · Beijing, China · NCT07441291

• Using CD22 CAR T-cells to extend remission after commercial CD19 CAR T-cell therapy in children, adolescents, and adults with relapsed/refractory B‑ALL

  This will try giving CD22-targeted CAR T-cells to people aged 3–65 who are in remission after CD19 CAR T-cell therapy to see if it helps keep their B-ALL from coming back longer.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07328503

• KSV01 injection for adults with relapsed or refractory B‑cell acute lymphoblastic leukemia

  This will test a new KSV01 CAR therapy injection to see if it is safe and helps adults with relapsed or refractory B‑cell acute lymphoblastic leukemia.

  Recruiting Phase 1 Zhejiang University · Hangzhou · NCT07246707

• Senl_B19 (S1904) CD19 CAR-T for relapsed or refractory CD19+ B-ALL in children and young adults

  This trial will test S1904 (Senl_B19) CD19 CAR-T cells in children and young adults aged 3–25 with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia.

  Recruiting Phase 2 Hebei Senlang Biotechnology Inc., Ltd. · Beijing · NCT07244406

• Using CAR-T cell therapy for treating relapsed and refractory blood cancers

  This study is testing a new CAR-T cell therapy to see if it can help people with tough-to-treat blood cancers like lymphoma and leukemia feel better.

  Recruiting Phase 1/2 Tianjin Medical University General Hospital · Tianjin, Tianjin Municipality · NCT06911710

• Nutrition and exercise during hospital induction for adults with Philadelphia chromosome–negative B‑ALL

  This program will test whether guided nutrition and in-hospital exercise during induction therapy help adults with Philadelphia chromosome–negative B‑ALL keep muscle and limit excess body fat.

  Recruiting University of Chicago · Chicago, Illinois · NCT06785324

• JY231 injection for relapsed or refractory B‑cell lymphoma and leukemia

  This trial will test whether a single intravenous JY231 injection, given with or without short lymphodepletion, can help adults with relapsed or refractory CD19‑positive B‑cell lymphoma or B‑ALL.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06689917

• JY231 injection for treating relapsed or refractory B cell lymphoma and leukemia

  This study is testing a new injection called JY231 to see if it can help people with relapsed or hard-to-treat B cell lymphoma and leukemia feel better.

  Recruiting Shenzhen Genocury Biotech Co., Ltd. · Zhenzhou, Henan · NCT06678282

• Evaluating the delayed effects of CAR T cell therapy in children

  This study looks at the short-term and long-term side effects of CAR T cell therapy in children with certain types of cancer to see how it affects them over time.

  Recruiting at 7 sites St. Jude Children's Research Hospital · Los Angeles, California and 6 other locations · NCT06579469

• Evaluating blood tests to monitor recovery after CAR T-cell therapy in young patients with leukemia

  This study is testing new blood tests to help doctors keep an eye on young patients with leukemia after their CAR T-cell therapy to see who might need extra treatment and who can stay healthy without it.

  Recruiting at 8 sites National Institutes of Health Clinical Center (CC) · Los Angeles, California and 7 other locations · NCT05621291

• New CAR T-cell therapy for children and young adults with certain blood cancers

  This study is testing a new CAR T-cell therapy that uses modified cells from children's and young adults' own blood to see if it can help treat certain tough-to-treat blood cancers.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05442515

• Treatment using CD19 and CD22 targeted CAR-T cells for relapsed B-ALL

  This study is testing a new CAR-T cell treatment that targets both CD19 and CD22 to see if it can help patients with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia feel better.

  Recruiting Phase 1/2 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT04781634

• CD123-CAR T-cell therapy for treating acute myeloid leukemia and related conditions

  This study is testing a new type of T-cell therapy to see if it can safely help young people with certain types of leukemia and related blood disorders.

  Recruiting at 2 sites Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee and 1 other locations · NCT04318678

NIH-funded research (12)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Preventing childhood B-ALL through maternal diet and TVA intake

  A study at Loyola University Chicago will explore whether a mother’s intake of TVA during pregnancy can help prevent childhood B-ALL in babies.

  NIH research Loyola University Chicago · Maywood, United States · NIH-11447223

• Metabolic drivers of B-ALL diversity and relapse risk

  A study at Stanford will explore how diverse B-cell receptor rearrangements and their metabolism shape relapse risk in children and adults with B-ALL, with the goal of improving detection and treatment.

  NIH research Stanford University · Stanford, United States · NIH-11434237

• Donor CAR T Cells Added to Transplant to Prevent Relapse in adults with B-ALL

  A new approach combines donor CAR-T cells targeting CD19 and CD22 with a stem cell transplant to lower relapse risk in adults with B-ALL.

  NIH research Stanford University · Stanford, United States · NIH-11400088

• Improving CAR T-cell therapy for pediatric B-ALL

  A physician-scientist at St. Jude aims to advance CAR T-cell therapy for children with high-risk B-ALL by testing new donor-derived and enhanced autologous CAR T-cell approaches in early-phase trials.

  NIH research St. Jude Children's Research Hospital · Memphis, United States · NIH-11386624

• Understanding how genetics contribute to childhood B-ALL (a type of leukemia)

  Aims to map genetic risk factors that lead to relapse or development of B-cell acute lymphoblastic leukemia in children, with a focus on diverse populations.

  NIH research Boston Children's Hospital · Boston, United States · NIH-11379150

• Targeting VAV3 and ERa to treat high‑risk B-ALL in adults and children

  This grant tests a new treatment strategy that combines a VAV3 inhibitor with an estrogen receptor degrader to help patients with difficult-to-treat B-ALL, including relapsed cases.

  NIH research Cincinnati Childrens Hosp Med Ctr · Cincinnati, United States · NIH-11364664

• Off-the-shelf regulatory T cell therapy for blood cancers (CAR-T Tregs)

  A patient-focused look at a potential cell therapy that uses donor-derived regulatory T cells engineered to attack certain blood cancers.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11324630

• Donor CAR T cells targeting CD19 and CD22 to prevent relapse in adult B‑ALL

  Adults with B‑cell acute lymphoblastic leukemia receive a donor stem‑cell transplant with regulatory T cells followed by donor CAR T cells that target CD19 and CD22 to try to lower the chance the leukemia comes back.

  NIH research Stanford University · Stanford, United States · NIH-11197508

• Understanding Genetic Differences in Childhood B-Cell Leukemia

  This research aims to uncover the specific genetic changes that contribute to childhood B-cell acute lymphoblastic leukemia (B-ALL), especially in children of Hispanic/Latino ethnicity.

  NIH research Boston Children's Hospital · Boston, United States · NIH-11136407

• Understanding genetic factors that increase the risk of childhood leukemia

  This study is looking into the genetic reasons behind B-cell acute lymphoblastic leukemia (B-ALL) in kids, especially focusing on Hispanic/Latino children, to find ways to prevent this common type of leukemia by understanding how certain genes affect the growth of B cells.

  NIH research Boston Children's Hospital · Boston, United States · NIH-10941649

• Targeted therapy for relapsed B-cell leukemia and lymphoma using CAR T-cells

  This study is testing a new treatment for adults with tough-to-treat B-cell leukemia and lymphoma, using special CAR T-cells along with a unique method to help make the treatment safer and more effective.

  NIH research Actinium Pharmaceuticals, INC. · New York, UNITED STATES · NIH-10892773

• Improving CAR T-cell therapy for children with leukemia

  This study is looking at a new kind of CAR T-cell therapy for kids with B-cell Acute Lymphoblastic Leukemia (B-ALL) to see if using special donor cells can make the treatment safer and more effective, while also helping the cells stay in the body longer to keep the cancer from coming back.

  NIH research St. Jude Children's Research Hospital · Memphis, United States · NIH-10807843

Related topics

Quick answers

How many B-ALL clinical trials are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (7 trials), United States (7 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 3, Phase 1/2: 3, Phase 2: 2, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →